India Rejects Cancer Drug Patent
Generic version will still be available.

Manish Swarup/AP,Manish Swarup
Get the Beast Digest newsletter delivered straight to your inbox
By clicking “SIGN UP” you agree to our Terms of Use and Privacy Policy.
India’s Supreme Court decided Monday that it will not allow drug manufacturer Novartis AG to patent an updated version of the cancer drug Glivec, ensuring that a generic version of the medicine will continue to be available and affordable for poor patients around the world. Health activists opposed Novartis’s attempt to acquire a patent on the update—arguing that the medicine was not new, and allowing drug companies to extend patents on drugs every time a minor change is made would halt generic manufacturers from producing those drugs at a much lower cost. While the decision is a win for India’s $26 billion generic-drug industry—responsible for providing much of the cheap medicine used in the developing world—Novartis called it “a setback for patients,” arguing that “patents safeguard innovation and encourage medical progress.”
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation
Sign in or create an account
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation